Published Date: 02 Mar 2023
In people with type 1 diabetes, the immune system attacks and destroys insulin. The cells that control blood sugar and are part of the cells of the pancreas are called islets. Looking for...
Read Full Newsargenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.
Early initiation of opicapone significantly reduces OFF time and enhances ON time in patients with recently diagnosed Parkinson's disease, improving overall treatment outcomes.
The FDA requested the full data from the phase 3 HOPE-3 study as part of its review of the biologics license application for deramiocel, which Capricor plans to submit in February 2026.
A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.
Personalized Care Improvements Identified for Older Patients with Skin Cancer
New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc
What to Expect at the 2026 Maui Derm Conference
1.
De-Intensified Therapy Misses Mark in HPV-Positive Oropharyngeal Cancer
2.
An "exploding" field of antibody-drug conjugates is making progress against ovarian cancer.
3.
Mobile prostate cancer screening clinic can ID the disease in disadvantaged men
4.
The most precise research tools for the deadliest blood cancer have been developed.
5.
EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer
1.
The Mystery of Carotid Body Tumors: The Facts You Need to Know
2.
Survival Rates in Cancer: Focus on Acute Myeloid Leukemia and Other Malignancies
3.
From Autoimmune Disorders to COVID-19: How Plasmapheresis Is Revolutionizing Modern Medicine
4.
Leukemia: Understanding the Disease and Its Impact on Patients
5.
Uncovering the Mysteries of Breast Cancer: The Journey to a Cure
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
2.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Navigating the Complexities of Ph Negative ALL - Part X
5.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation